In the United States, the Center for Medicare and Medicaid Innovation, or CMMI, has announced two new mandatory models that propose Most-Favored-Nation, or MFN, pricing using specified international benchmarks for certain products covered by Medicare and one new voluntary model that proposes MFN pricing for products covered by Medicaid.
All entries for: Pharming Group N.V.
April 2, 2026
Pharming Group N.V.
Neutral Outlook
New York, NY
1-50 employees
On August 16, 2022, President Biden signed the IRA into law. The IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation.
Disease Area: Immune Diseases, Metabolic Diseases, Rare Diseases
Drug Type: Small Molecule